| Literature DB >> 25662412 |
Olivia Pagani1, Monica Ruggeri2, Silvia Manunta3, Christobel Saunders4, Fedro Peccatori5, Fatima Cardoso6, Bella Kaufman7, Shani Paluch-Shimon7, Hanan Gewefel8, Elisa Gallerani9, O Malkahi Abulkhair10, Barbara Pistilli11, Ellen Warner12, Emmanouil Saloustros13, Lucien Perey14, Khalil Zaman15, Manuela Rabaglio16, Shari Gelber17, Richard D Gelber17, Aron Goldhirsch18, Larissa Korde19, Hatem A Azim20, Ann H Partridge21.
Abstract
Young patients with breast cancer (BC) are often concerned about treatment-induced infertility and express maternity desire. Conception after BC does not seem to affect outcome, but information in estrogen-receptor positive (ER+) disease is not definitive. From September 2012-March 2013, 212 evaluable patients with ER+ early BC, <37 years at diagnosis, from 5 regions (Europe/US/Canada/Middle-East/Australia) answered a survey about fertility concerns, maternity desire and interest in a study of endocrine therapy (ET) interruption to allow pregnancy. Overall, 37% of respondents were interested in the study; younger patients (≤30 years) reported higher interest (57%). Motivation in younger patients treated >30 months was higher (83%) than in older women (14%), interest was independent of age in patients treated for ≤30 months. A prospective study in this patient population seems relevant and feasible. The International-Breast-Cancer-Study-Group (IBCSG), within the Breast-International-Group (BIG) - North-American-Breast-Cancer-Groups (NABCG) collaboration, is launching a study (POSITIVE) addressing ET interruption to allow pregnancy.Entities:
Keywords: Breast cancer; Endocrine treatment; Estrogen receptor; Pregnancy; Young patients
Mesh：
Substances：
Year: 2015 PMID： 25662412 DOI： 10.1016/j.breast.2015.01.005
Source DB: PubMed Journal: Breast ISSN： 0960-9776 Impact factor: 4.380